Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeeing Machines Regulatory News (SEE)

Share Price Information for Seeing Machines (SEE)

Share Price is delayed by 15 minutes
Get Live Data
4.65    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.05 (1.075%)
Market Cap: £223.18m
SEE Live PriceLast checked at - London Stock Exchange

Intraday Seeing Machines Share Chart

Licensing agreement signed

22 May 2007 11:15

Seeing Machines Limited22 May 2007 22 May 2007 Seeing Machines Limited ("Seeing Machines" or the "Company") SEEING MACHINES LICENSES faceAPI PRODUCT Seeing Machines (AIM: SEE), a leading developer of advanced computer basedimaging software systems, announces today that the Company has signed atechnology licensing agreement with a North American based computer visioncompany. Seeing Machines will provide its unique faceAPI based head trackingtechnology to the client for use within their applications. Seeing Machines willreceive a license fee for each product sold that incorporates the faceAPIproduct. The terms of the licensing agreement are the subject of aconfidentiality agreement and have not been disclosed. Nick Cerneaz, CEO of Seeing Machines, commented: "Signing this agreement isdirectly aligned with our business strategy to generate revenue from licensingour core technology to other product and application developers. This licensingagreement builds on the foundations for our faceAPI business laid over the last2 years of development and we are looking to build this line of our businessfurther in the coming year." Further information about Seeing Machines can be obtained from the companywebsite www.seeingmachines.com. --- ENDS --- Enquiries: Seeing Machines Limited Insinger de Beaufort Parkgreen CommunicationsNick Cerneaz, CEO Peter Ward Erica Nelson+61 (0) 2 6125 6501 +44 (0) 20 7190 7015 +44 (0) 20 7851 7480www.seeingmachines.com Notes to editors: About Seeing Machines Seeing Machines is an award winning Technology Company which focuses on visionbased human machine interfaces. Formed in 2000 in Canberra, Australia, SeeingMachines' purpose is to commercialise its computer-vision across a range ofindustries and applications. Seeing Machines deliver advanced computer vision solutions for researches anddevelopers in human factors, transportation safety, computer human interaction,robotics, medical research and psychology. The flagship product faceLAB(R)provides an automated and contact-free gaze and head tracking technology, itsolves the problem of observing human behaviour naturally, non-intrusively andwith a high degree of accuracy and usability. The underlying head pose, eye gazeand facial feature tracking technologies within faceLAB(R) are also packaged inthe faceAPITM product that is available to third party integrators andapplication developers allowing them to incorporate that functionality in theirown developments. Building on these unique face tracking and pupil measurement and monitoringcapabilities, Seeing Machines is also developing the TrueField Analyzer(R), anew ophthalmic device to help clinicians detect and manage glaucoma (and a rangeof other diseases of the human visual system). Seeing Machines' faceLAB(R) product is a computer vision system that is able tomeasure the orientation and position of a human head, as well as detect blinksand estimate gaze-direction. It achieves all of this completely visually througha stereo camera system connected to advanced image processing software, with noattachments required on the subject. The product is designed to allow humanfactors researchers and designers assess the interaction of an operator in anenvironment and this finds application in designing operator environments, suchas cockpits for cars, trucks, trains, and aeroplanes for instance, and otherindustrial design applications, as well as medical and psychological researchsituations. The technology also has application in monitoring automobile driversand if it detects drowsiness or that the driver is distracted and theirattention has been diverted from the road, an alarm can be raised to alert thedriver to either pull over and rest in the case of drowsiness or to pay moreattention to the road. faceLAB(R) works in real-time, enabling the behaviour of a subject to betracked. This technology is paving the way in promoting safer driving conditionsand works to enhance the driving experience and to eliminate accidents causedthrough driver drowsiness or distraction. In addition to the capabilities outlined above the faceAPITMsuite also includesextensive monocular tracking solutions, high precision eye and pupil trackingand monitoring capabilities, advanced automatic initialization and automaticbackground operating modes. The product is a fully featured solution allowingboth automated and manual control modes and providing the host application withextensive information about the user(s) being monitored by the tracking system. There are many different sectors that can benefit from this revolutionarysoftware, for which it has been developed, including: automotive; academicresearch; medicine/healthcare; defence; autostereoscopy (next generationdisplays); sport; and games. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
12th May 20267:00 amRNSUS$3.8m Order for Guardian BdMS
6th May 20267:00 amRNSQ3 FY2026 Quarterly KPIs
20th Apr 202612:30 pmRNSHolding(s) in Company
10th Apr 20268:53 amRNSStatement re alleged cyber threat
27th Mar 20267:00 amRNSHalf-year Financial Report
24th Feb 20267:00 amRNS-RPublication of Investor Presentation
18th Feb 20267:00 amRNSTrading Update - H1 FY2026
13th Feb 20267:30 amRNSAppointment of Joint Broker
11th Feb 20267:00 amRNSQ2 FY2026 Quarterly KPIs
13th Jan 202612:00 pmRNS-R3D Cabin Perception Mapping breaks new ground
6th Jan 20267:00 amRNSAgreement
5th Jan 20267:00 amRNS-R3D Cabin Perception Mapping to be unveiled at CES
5th Jan 20267:00 amRNSHolding(s) in Company
2nd Jan 20267:00 amRNS-RSeeing Machines Announces Future Mobility Group
2nd Jan 20267:00 amRNS-RSeeing Machines Announces Future Mobility Group
17th Dec 20257:00 amRNS-RTechnical Paper Series - Intoxication launched
4th Dec 20257:00 amRNS-RSeeing Machines 2025 Guardian Insights Report
27th Nov 20257:00 amRNSResults of AGM
26th Nov 20257:30 amRNSJapanese Auto Award and Extended European Program
12th Nov 20257:05 amRNSQ1 FY2026 Quarterly KPIs
12th Nov 20257:00 amRNSGuardian order from US-based multinational company
6th Nov 20257:05 amRNS-RCollaboration with Magna milestone in China
3rd Nov 20257:00 amRNSBoard Changes
3rd Nov 20257:00 amRNSNotice of Annual General Meeting
30th Oct 20257:00 amRNSLATAM Distributor Orders 1,300 Guardian Units
29th Oct 20257:00 amRNSAdvanced Development Project with Japanese OEM
8th Oct 20257:00 amRNSUS$1.8m expansion order for Guardian BdMS
26th Sep 20257:00 amRNSExpanding Guardian prospects across Europe
25th Sep 20257:00 amRNSFY2025 Results and Annual Financial Report
24th Sep 20257:20 amRNSFirst Guardian contract through Mitsubishi
10th Sep 20257:05 amRNS-RSeeing Machines Launches Impairment Capability
10th Sep 20257:00 amRNSNotice of Results and Presentation
29th Aug 202510:10 amRNSDirector Dealing
21st Aug 20257:00 amRNSFY2025 Trading Update
5th Aug 20257:00 amRNSQ4 FY2025 Quarterly KPIs
30th Jun 20257:00 amRNSMitsubishi Electric Europe Guardian collaboration
27th Jun 20257:00 amRNSUS Guardian Gen 3 trial with Mitsubishi Electric
16th Jun 20258:59 amRNS$1.2 Million Agreement with Global Auto Leader
9th May 20252:31 pmRNSDirector dealing
1st May 20257:00 amRNSQ3 FY2025 Quarterly KPIs
29th Apr 20259:58 amRNSNotification of Major Holdings
8th Apr 20258:53 amRNSHoldings in Company
8th Apr 20257:00 amRNSDirector/PDMR Shareholding
4th Apr 20257:00 amRNSDirector dealing
2nd Apr 202511:00 amRNSLondon presentation for investors and analysts
2nd Apr 20257:00 amRNSDirector dealing
2nd Apr 20257:00 amRNSDirector dealing
1st Apr 202512:00 pmRNS-RSeeing Machines Announces 3D Camera Technology
31st Mar 20257:00 amRNSDirector/PDMR Shareholding
28th Mar 20257:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.